In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens
In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens
复制标题
DOI：
10.1159/000007096
复制
发表时间：
1998-03-01
期刊：
影响因子：
3.3
通讯作者：
Witte, W
中科院分区：
文献类型：
--
作者：
Naber, KG;Well, M;Witte, W
采用琼脂稀释法测定了依诺沙星、环丙沙星、氟罗沙星、洛美沙星、氧氟沙星、培氟沙星和鲁氟沙星对400种泌尿系统病原体的最低抑制浓度（MIG），这些病原体培养自复杂和/或医院获得性尿路感染（UTI）患者的尿液。细菌谱由肠杆菌科（34.5%）、肠球菌（31.5%）、葡萄球菌（21.2%）和非发酵菌（12.8%）组成。依诺沙星对肠杆菌科除一株阴沟肠杆菌外的所有菌株均有抑制作用，MIC为1 mg/l （MIC90为0.25 mg/l）。在MIC分别为1、2、4和8 mg/l时，依诺沙星对总菌谱的抑制作用分别为54.5、59.5、76.0和83.8%。如果对其他氟喹诺酮类药物也采用DIN 58 940 （ncls）规定的氧氟沙星耐药断点，即MIC大于或等于4 mg/l（大于或等于8 mg/l），并排除126株肠球菌，而应考虑使用氨霉素等替代药物，则发现以下耐药率：环丙沙星、依诺沙星15.3%（15.0%）、氧氟沙星17.2%（15.3%）、培氟沙星18.2%（15.3%）、氟罗沙星19.3%（15.3%）、洛美沙星19.7%（17.9%）、鲁氟沙星31.8%（27.4%）。根据其体外活性，除鲁氟沙星外，所有测试的氟喹诺酮类药物对尿路病原体的耐药率相似，因此可以被认为是治疗复杂尿路感染的良好替代药物。
Minimum inhibitory concentrations (MIG) of enoxacin, ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin and rufloxacin were determined against 400 uropathogens cultured from the urine of patients with complicated and/or hospital-acquired urinary tract infections (UTI) using an agar dilution method. The bacterial spectrum consisted of Enterobacteriaceae (34.5%), enterococci (31.5%), staphylococci (21.2%) and non-fermenting bacteria (12.8%). Enoxacin inhibited all but one strain (Enterobacter cloacae) of Enterobacteriaceae up to an MIC of 1 mg/l (MIC90 0.25 mg/l). Regarding the total bacterial spectrum, enoxacin inhibited 54.5, 59.5, 76.0 and 83.8% up to an MIC of 1, 2, 4 and 8 mg/l, respectively. If the same breakpoint of resistance for ofloxacin according to DIN 58 940 (NCCLS), i.e. MIC greater than or equal to 4 mg/l(greater than or equal to 8 mg/l), is also taken for the other fluoroquinolones, and the 126 strains of enterococci are excluded, for which alternative agents, e.g. aminopenicillins, should be considered instead, the following resistance rates were found: ciprofloxacin and enoxacin 15.3% (15.0%), ofloxacin 17.2% (15.3%), pefloxacin 18.2% (15.3%), fleroxacin 19.3% (15.3%), lomefloxacin 19.7% (17.9%) and rufloxacin 31.8% (27.4%). According to their in vitro activity, all fluoroquinolones tested besides rufloxacin show similar rates of resistance against uropathogens and can therefore be considered good alternative agents for the treatment of complicated UTI.